key: cord-0912386-aar38bo6 authors: Vas, PRJ; Hopkins, D; Feher, MD; Rubino, F; Martin, MB title: Diabetes, Obesity and COVID‐19: A Complex Interplay date: 2020-07-06 journal: Diabetes Obes Metab DOI: 10.1111/dom.14134 sha: f6a15bdbf5d45eeafc6fff3454d2909e7e761591 doc_id: 912386 cord_uid: aar38bo6 With the accumulation of observational data showing association of metabolic comorbidities with adverse outcomes from COVID‐19, there is a need to disentangle the contributions of pre‐existing macro‐ and microvascular disease, obesity and glycaemia. This article outlines the complex mechanistic and clinical interplay between diabetes and COVID‐19, the clinical and research questions that arise from these; and the types of studies needed to answer them. The authors are clinicians and academics working in diabetes and obesity medicine, but the article is pitched to an audience of generalists with clinical experience or interest in management of COVID‐19. This article is protected by copyright. All rights reserved. As the global COVID-19 pandemic has evolved, a surprising feature has been a transition in its perception from a condition of greatest risk to those with chronic pulmonary disease, to one where the threat predominates in those with diabetes and metabolic dysfunction. In large case series COPD was present in only i1% in China 1 ; 5% in United States 2 ; and 18% in the UK, 3 but in contrast diabetes was present in 8% 1 ; 33.8% 2 ; and 21% 3 of cases, respectively. In addition, marked insulin resistance with ketosis has been reported 4,5 even in those with no preceding history of diabetes. 6, 7 These observations suggest an interplay between COVID-19 and diabetes, and a complex pathophysiology. Understanding how diabetes can lead to severe COVID-19 and conversely, how COVID-19 can complicate diabetes pathophysiology or its outcomes, is an important priority for clinical practice and public health. To address this, a global registry (COVIDiab) has been launched to facilitate the study of the manifestations of COVID-19 related diabetes, its outcomes, and best treatment. 9 Over the short duration of the COVID-19 pandemic, a wealth of data has emerged on this topic but there remain significant questions that need to be answered. Here we review the existing literature on the interplay between COVID-19 and diabetes and consider the priorities for future research. Epidemiological studies have shown that diabetes increases the risk of hospitalisation, 10 admission to critical care 11 and mortality due to COVID-19. 2,12-15 Individuals with diabetes have accounted for 7.8% -33% of all hospital deaths. 13, 16, 17 One early multicentre study from Wuhan reported that the risk of fatal outcome was up to 1.49 times higher in patients with diabetes 17 ; however, a report from the United Kingdom, which examined 23,804 COVID-19 related deaths, has suggested that the mortality risk could be up to 2-3 times greater in those with diabetes. 13 Other studies have reported a two-fold increased risk for admission to critical care and an increased requirement for mechanical ventilation, compared with those who did not have diabetes. 2, 11, 17 Pooled analyses from these early studies have indicated prevalence rate of diabetes between 9.% to 11.5%, after adjusting for heterogeneity. 18, 19 Likewise, metanalyses of early studies have suggested a two-to threefold increase in the risk of severe forms of COVID-19 including critical admissions, and mortality in diabetes. 18, [20] [21] [22] Diabetes may also predispose to comorbidity in the context of COVID-19 infection, as has been reported for acute stroke. 23 There are, at present, limited data on the true case fatality rate in diabetes compared to other conditions and comorbidities. This has left several unanswered questions, the first of which being: what is the generalisability of these reported data? Most of the published data have been derived from hospital statistics, which can introduce selection bias. In many countries, communities outside of secondary-care centres had limited access to COVID-19 testing, resulting in diagnostic access bias, which may exaggerate overall severity and distort the case fatality rate (CFR). With this caveat, there seems to be worldwide consistency in the high prevalence of diabetes in hospitalised patients, as well as an association between severity of COVID-19 (variously defined as requirement for critical care, invasive ventilation, or death) and diabetes. Although type of diabetes is not always differentiated, severe COVID-19 has been reported for both type 1 and type 2 diabetes. Where reported separately, the relative risk appears greater for type 1 diabetes but this may need to be interpreted with caution as overall case numbers are low. 24 If diabetes does influence the outcomes of COVID-19, is that through susceptibility to COVID-19 infection? Or via the immune response? Myriad defects of the innate response have been reported in diabetes, including dysfunction of granulocytes, monocyte/macrophages, dendritic cells, natural killer (NK) cells, B cells, T cells, and cytokine signalling. 25, 26 Unsurprisingly, the risk of bacterial and fungal infections is increased among patients with diabetes. 27 However, aside from the Hepatitis virus C, 28 and herpes zoster, 29 there is little evidence that diabetes, or the level of glycaemic control, predisposes to the chance of viral infection. 30 Data from outside the hospital setting, centred in primary care, is needed to determine whether the presence of diabetes (and/or degree of glycaemic control) affects the infection rate of COVID-19. In addition to this, there may be additional specific mechanisms for dysglycaemia in COVID-19. The SARS-CoV2 virus may gain selective entry to pancreatic islets via the ACE-2 receptor and lead to local cytopathic effects, diminishing beta-cell function. 31 Furthermore, ACE-2 receptors are highly prevalent in other metabolic organs and tissues including adipose tissue, the liver and the small intestine, providing a plausible mechanistic explanation for the observed marked insulin resistance in Critical illness is characterised by a neuro-endocrine response including sympathetic nervous system activity, hyperglucagonaemia, cortisol and growth hormone release. 33 These all have the effect of inducing resistance to insulin action in multiple tissues, resulting in hyperglycaemia. In critical care, glucose clamp studies show greater insulin resistance with more severe medical illness -determined by the Acute Physiology and Chronic Health Evaluation II (APACHE II) score. 34 Microthrombi, a hallmark of COVID-19 pathology, 35 may compound impaired glucose disposal from pre-existing diabetic microangiopathy. 36 Likewise, blood glucose concentration may be a surrogate marker for disease severity in COVID-19. To date, there are no data that correlate COVID-19 disease severity to blood glucose and to do this there needs to be consensus on a robust measure of severity. At present, validated measures of COVID-19 severity are lacking. A small series, exploring the predictive value of established severity measures, suggested some superiority of the APACHEII scale over the Sequential Organ Failure Assessment (SOFA) score and CURB-65 score. 37 Further validation of these illness-severity scores are needed for COVID-19. At a systemic level, attempts should be made to evaluate the potential role of complications and comorbidities of diabetes in COVID-19 outcomes. These should include obesity, obstructive sleep apnoea, hypertension and macrovascular disease -all of which have figured prominently as risk factors, 1-3 but also microvascular disease. Measured microvascular dysfunction (such as nephropathy, retinopathy or neuropathy) in one organ may be a manifestation of more systemic involvement, that could include the peri-alveolar microvasculature. 36, 38 The dissociation between preserved lung mechanics and the severity of hypoxaemia has led to an observation that respiratory failure in COVID-19 is 'atypical' 39, 40 , characterised by a form of catastrophic microvascular injury syndrome mediated by activation of complement pathways alongside a procoagulant state. 41 Microthrombi and 'endothelitis' 35 may contribute further to the impediment of microvascular blood-flow and gas transfer in the lung, 42 increasing disease severity. Microangiopathy of diabetes may be an independent risk factor for severity of COVID-19 and requires further study. Defining the prognostic value of metabolic alterations in acute COVID-19 is crucial to inform clinical practice. However, there are currently no data to assist us in such assessment. Since diabetes increases severity of COVID-19, it makes intuitive sense to aggressively treat this; it is not clear, however, what parameters should guide the escalation of therapeutic options. Is it the HbA 1c , the admission glucose, or the mean/variance of the in-hospital glucose? In the CORONADO study, undertaken on 1317 participants across 53 French centres admitted to hospital with diabetes and COVID-19, the most recent HbA 1C pre-admission did not independently predict death or need for intubation. 12 In this study, as in the large UK cohort, 24 Concerns have also been raised that individuals from black, Asian and minority ethnic backgrounds (BAME) are at disproportionate risk of contracting the virus, 44 admission to critical care 3 and mortality from COVID-19. 45, 46 In the UK cohort, a higher risk of death was noted in the black and Asian population for both type 1 and type 2 diabetes. 13 In the CORONADO study, 38.1% of all admissions with diabetes were from BAME backgrounds. 12 Potential confounders for ethnicityeffect include the well-recognised higher prevalence of diabetes, obesity and hypertension in BAME populations and socio-economic deprivation; but factors such as disparities in glycaemic control and access to care may also contribute. 44, 47 The need for focus in future research direction The recognition of the association between diabetes and COVID-19 is only the beginning of our understanding of the interplay between these two conditions; work is needed to understand the mechanisms and directionality of that relationship. Whether the association of diabetes with poor outcomes is direct, or secondary to co-morbidities, needs clarification. Epidemiologic studies must assess diabetes groups stratified with respect to ethnicity, diabetes complications, and therapies to further understand susceptibility to primary infection and risk of developing severe disease. Some striking findings have been noted in data already published; a strong association between diabetes and poor outcome has been noted in younger (<55 years) and less hypertensive individuals 20 as well as those hitherto unrecognised to have diabetes. 50 Given the latter finding, screening all admissions to hospital for hyperglycaemia and instituting early treatment where needed is important. 51 The atypical presentation of diabetes -with ketosis and marked insulin resistance -in COVID-19 creates specific challenges in management. In recognition of this, specific guidance based on theoretical principles has emerged 52,53 , but evidence of the efficacy of management strategies is needed. Published guidance has raised theoretical concerns surrounding the safe use of SGLT-2 inhibitors and metformin, 54, 55 although, as yet, there are no systematic studies exploring outcomes and impact. Human dipeptidyl dipeptidase 4 (DPP4) is a Coronavirus receptor, suggesting a potential role for DPP-4 inhibitors in COVID-19 56 -however early evidence has shown no reduction in hospitalisation with their use. 57 Corroborative data are required for the observation of a lower risk of death (hazard ratio 0.14) in those with normoglycaemia in hospital, 17 as this will affect glucose targets. It may be that avoidance of marked hyperglycaemia, rather than attaining normoglycaemia (with associated risk of hypoglycaemia) should be the goal for in-hospital management. This question has assumed particular importance following the finding that dexamethasone treatment significantly improved outcomes in oxygenated and ventilated patients with COVID-19 in the RECOVERY trial. 43 In light of this, utilisation of corticosteroids is likely to become standard practice in severe COVID-19 therefore defining an acceptable glucose target range and diabetes management strategy for these patients will be of utmost importance. Of note, one quarter of the RECOVERY study population had diabetes mellitus and post-hoc analyses are awaited for whether individuals with diabetes had similar outcomes with steroid therapy, to the wider population. Accumulating data of the disproportionate risk to BAME populations with diabetes requires rigorous scrutiny, given the broader implications on public health and social equity. 58 Vaccine studies should also be designed to include people with diabetes and from BAME groups in sufficient numbers to allow evaluation of within these high-risk groups. Mechanistic studies are needed to determine the effect of COVID-19 on tissue-specific insulin resistance, the impact on pancreatic B-cell dysfunction, and lung diffusion and perfusion dynamics in the presence of hyperglycaemia. Clinical studies to evaluate therapeutic strategies to ameliorate the severity of an infection need also assess potential drug interactions with diabetes therapies. Further characterisation of the unusual properties of diabetes seen in COVID-19 is needed -to this end, a global registry (COVIDiab) 9 has been set up to define the characteristics of new-onset diabetes in affected individuals. Long-term observational follow-up of COVID-19 survivors is also required to determine if there is an increased risk of DM after COVID-19 (as with 2002 SARS) and whether it impacts on progression to insulin or worsening microvascular disease during late follow-up. The impact of 'lockdown' on glycaemic control care among individuals with diabetes will be of considerable interest to health care professionals, epidemiologists and to policy makers. Changes in physical activity, weight gain, behaviours and social isolation 59 brought on by the lockdown will have important clinical ramifications. Studies investigating changes in glycaemic control during this period of enforced sedentary lifestyle and the 'legacy effects' of lockdown are awaited. The landscape surrounding access to care seems to have also rapidly shifted with the adoption of various telehealth initiatives, which are yet to be properly validated to confirm effectiveness in delivering diabetes care. 60 Detailed studies exploring these new models are urgently required as health system prepare to embark on post-COVID-19 recovery plans. Such initiatives also support medical preparedness 61 should a second wave of the pandemic appear. Given that COVID-19 is likely to persist for the foreseeable future, and the high global prevalence of diabetes it is imperative that research in these areas is prioritised to provide support for optimised clinical management and health policy formulation. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study Guidance on the management of Diabetic Ketoacidosis in the exceptional circumstances of the COVID-19 pandemic COVID-19 infection may cause ketosis and ketoacidosis Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus COVID-19 infection may cause ketosis and ketoacidosis New Onset Diabetes in Covid19: A Global Registry New-Onset Diabetes in Covid-19 Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 -United States Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study Type 1 and Type 2 diabetes and COVID-19 related mortality in England Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 -United States Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis Prevalence of comorbidities and their association with mortality in patients with COVID-19: A Systematic Review and Meta-analysis Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia -A systematic review, meta-analysis, and metaregression Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis Influence of diabetes mellitus on the severity and fatality of SARS-CoV-2 (COVID-19) infection Prevalence and Outcomes of Acute Ischemic Stroke Among Patients ≤ 50 Years of Age with Laboratory Confirmed COVID-19 Infection Type 1 and Type 2 diabetes and COVID-19 related mortality in England: a whole population study Type 2 Diabetes: How Much of an Autoimmune Disease? Oxidant stress, immune dysregulation, and vascular function in type I diabetes Risk of Infection in Type 1 and Type 2 Diabetes Compared With the General Population: A Matched Cohort Study Type 2 diabetes mellitus and the risk of hepatitis C virus infection: a systematic review Risk Factors for Herpes Zoster: A Systematic Review and Meta-analysis Association between glycaemic control and common infections in people with Type 2 diabetes: a cohort study Endocrine and metabolic link to coronavirus infection Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis The neuroendocrine response to critical illness is a dynamic process Severity of insulin resistance in critically ill medical patients Endothelial cell infection and endotheliitis in COVID-19 Microvascular Dysfunction and Hyperglycemia: A Vicious Cycle With Widespread Consequences Acute Physiology and Chronic Health Evaluation II Score as a Predictor of Hospital Mortality in Patients of Coronavirus Disease The contribution of diabetic micro-angiopathy to adverse outcomes in COVID-19 COVID-19 Does Not Lead to a "Typical" Acute Respiratory Distress Syndrome Differentiating COVID-19 Pneumonia from Acute Respiratory Distress Syndrome (ARDS) and High Altitude Pulmonary Edema (HAPE): Therapeutic Implications Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome: Results From a Prospective, Single-Center Effect of Dexamethasone in Hospitalized Patients with COVID-19 COVID-19 and African Americans Is ethnicity linked to incidence or outcomes of covid-19? Evidence mounts on the disproportionate effect of COVID-19 on ethnic minorities Disparities in glycaemic control, monitoring, and treatment of type 2 diabetes in England: A retrospective cohort analysis Covid-19: Doctors sound alarm over hospital transmissions Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery The clinical characteristics and outcomes of patients with diabetes and secondary hyperglycaemia with coronavirus disease 2019: A single-centre, retrospective, observational study in Wuhan Why is hyperglycaemia worsening COVID-19 and its prognosis? Practical recommendations for the management of diabetes in patients with COVID-19 Therapeutic uncertainties in people with cardiometabolic diseases and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19) Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? Diabetes research and clinical practice Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications Exposure to DPP-4 inhibitors and COVID-19 among people with type 2 diabetes. A case-control study Equality, diversity and health inequalities Sanchis-Gomar F. Health risks and potential remedies during prolonged lockdowns for coronavirus disease 2019 (COVID-19) Telehealth in the Context of COVID-19: Changing Perspectives in Australia, the United Kingdom, and the United States Delayed access or provision of care in Italy resulting from fear of COVID-19